

GMP Compliance Menu

Search

[GMP Certificates](#)[Non-Compliance Report](#)[Print Preview](#)[Print Preview \(Short version\)](#)[Back To Search](#)**Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet**CERTIFICATE NUMBER : **OGYÉI/53372-6/2019****CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1), (2)****Part 1**

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Hungary confirms the following:

The manufacturer : **IOL Chemicals and Pharmaceuticals Ltd.**

Site address : **Village Fatehgarh Channa, Mansa Road (Trident Complex), Barnala, Punjab, 148101, India**

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2020-01-15** , it is considered that it complies with :

- The principles of GMP for active substances (3) referred to in Article 47 of Directive 2001/83/EC

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

(1) The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

(2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

(3) These requirements fulfil the GMP recommendations of WHO.

Part 2

Manufacture of active substance. Names of substances subject to inspection :

[15687-27-1] **IBUPROFEN (en)**

[84057-84-1] **LAMOTRIGINE (en)**

[1115-70-4] **METFORMIN HYDROCHLORIDE (en)**

[49562-28-9] **FENOFIBRATE (en)**

[120202-66-6] **CLOPIDOGREL HYDROGEN SULFATE (en)**

[164579-32-2] **PANTOPRAZOLE SODIUM SESQUIHYDRATE (en)**

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : **IBUPROFEN**

3.1 Manufacture of Active Substance by Chemical Synthesis

- 3.1.1 Manufacture of active substance intermediates
3.1.2 Manufacture of crude active substance
3.1.3 Salt formation / Purification steps :

3.5 General Finishing Steps

- 3.5.1 Physical processing steps :
3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

3.6 Quality Control Testing

- 3.6.1 Physical / Chemical testing
3.6.2 Microbiological testing excluding sterility testing

Active Substance : **LAMOTRIGINE**

3.1 Manufacture of Active Substance by Chemical Synthesis

- 3.1.1 Manufacture of active substance intermediates
3.1.2 Manufacture of crude active substance
3.1.3 Salt formation / Purification steps :

3.5 General Finishing Steps

- 3.5.1 Physical processing steps :
3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance : METFORMIN HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.1 Physical processing steps : 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance : FENOFIBRATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.1 Physical processing steps : 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance : CLOPIDOGREL HYDROGEN SULFATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.1 Physical processing steps : 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance : PANTOPRAZOLE SODIUM SESQUIHYDRATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.1 Physical processing steps : 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing

2020-03-16

Name and signature of the authorised person of the Competent Authority of Hungary

Confidential

National Institute of Pharmacy and Nutrition

Tel : **Confidential**

Fax : **Confidential**

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please [click here](#) to get list of NCA's.

Due to the restrictions caused by COVID-19, the period of validity of MIA's, WDA's, GMP and GDP certificates is automatically extended until the end of 2021. On-site inspections will resume as soon as there is a consensus that the period of the public health crisis has passed. The clarifying remark section of individual MIA's, WDA's, GMP and GDP certificates will indicate any exceptions. Competent authorities reserve the right to inspect a manufacturing site should the need arise.

As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period

[EMA © 2014. EudraGMDP 6.4.9.0 build 2020/06/19 13:20]